Drugs are modern magic. We expect medical drugs to ease pain, prevent sickness, and cure illness. Safely. Reliably. At lower cost is work in progress. We expect new drugs to work against more problems every year. Expectations meet reality with events like Covid-19. Science research and manufacturing came up with preventative vaccines very quickly compared to fearful expectations. Expectations for the mRNA Vaccine process are still expanding as the technology is used to build more, or improve, vaccines.
In this segment EkaLore looks at the lessons from disruptive introduction of mRNA technology into the global market for vaccines.
EkaLore has previously looked at the disruptive changes in the global vaccine production markets with the introduction and commercialization of mRNA technology Covid-19 vaccines. In this release, EkaLore looks briefly at what changes are seen after three years of the technology in the global marketplace.
Lessons from the introduction of Alien Technology (mRNA vaccine design, development, production, and mass inoculation) see lessons for any radical market disruption from a compelling need. These include:
High market landscape pressures for products of a new disruptive technology will see weaknesses in availability of materials, talents, and governance.
Competing technologies are still valuable to protect against changes in the cause of demand causing viability of a disruptive technology to be uncertain in the marketplace.
The levels of investment, regulatory and governance costs, and measuring benefits are much greater than originally believed requiring more planning and resources.
Diffusion and dissemination of a disruptive technology for more applications is much more difficult than originally believed giving advantage to colossal enterprises.
The rate of change and transitions driving adoption of a new technology can vary with time and marketplace expectations.
These lessons emerge from the global marketplace introduction of multiple mRNA produced Covid-19 vaccines. The lessons apply to expectations at global, governmental, investor, and enterprise levels. Managing expectations will be as much a struggle as mastering the technology and manufacturing requirements. Enterprises looking to invade the mRNA-based medical marketplaces need to deeply understand these lessons to find success.
The next segment will present the background and context for mRNA vaccines in global marketplaces.
The global marketplace was forced by successes to adopt mRNA-based vaccines. Public controversy still lingers after several years of marketplace experience. In part, controversies exist as a mismatch between expectations and experiences. The lessons from the creation , and marketplace Alien Invasion, of mRNA vaccines are lessons for all enterprises looking to invade marketplaces.
For additional information on Alien Invasions see http://www.ekalore.com
Comments